Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Steelhead Owns Nearly 6% of Enzon Pharmaceuticals

Steelhead Partners now owns 2.7 million shares of development-stage biotechnology company Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN). The 13G filed with the SEC has the fund, which is managed by Michael Johnston, owning 5.8% of the total shares outstanding; Steelhead had owned some of Enzon’s debt in its most recent 13F filing, but did not report any equity ownership (see Steelhead’s stock picks). The company’s products in development primarily consist of treatments for cancer patients. The stock is down 32% over the last year though in its most recent quarterly report Enzon held a large cash position.

Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN)

Loading...